Results 181 to 190 of about 18,271 (248)

Prior Authorization, Quantity Limits, and Step Therapy for Patient-Administered Antiemetics.

open access: yesJAMA Netw Open
Vu K   +5 more
europepmc   +1 more source

Antiemetic therapy

Critical Reviews in Oncology/Hematology, 2002
The emetogenic potential of cancer chemotherapeutic agents varies according to the agent employed. Among the highly emetogenic agents, cisplatin has been the most studied. As for emesis induced by cisplatin, an optimal antiemetic schedule is effective in 70-90% of cases of acute emesis, in 60% of cases of delayed emesis, whereas acute emesis induced by
L. Licitra, S. Spinazzé, F. Roila
openaire   +3 more sources

Economics of antiemetics

Current Opinion in Anaesthesiology, 2002
Numerous studies about postoperative nausea and vomiting management are available and meta-analyses have helped to define the appropriate doses of the effective drugs. Almost all recent papers include some economical considerations. In order to rationalize the therapeutic protocols, strategies including systematic prophylaxis, treatment of established ...
Pierre, Diemunsch, Anne-Marie, Diemunsch
openaire   +2 more sources

Antiemetics revisited

Current Opinion in Oncology, 1997
In the past few years a combination of a 5-HT3 receptor antagonist plus dexamethasone has been shown to be the most efficacious antiemetic prophylaxis of acute emesis induced by cisplatin and moderately emetogenic chemotherapy. In the prevention of cisplatin-induced delayed emesis oral metoclopramide or ondansetron, both combined with dexamethasone ...
F, Roila, A, Del Favero
openaire   +2 more sources

Home - About - Disclaimer - Privacy